The AI in Drug Discovery Xchange event brings together senior-level scientists and executives from the pharmaceutical and biotech sectors to tackle key challenges in Data Quality, Target Identification, Lead Generation & Optimization and Drug Response Prediction.
Digital Science are delighted to be presenting the opening keynote, and facilitating a roundtable discussion at this year’s event.
Keynote: AI and the Perpetual Research Cycle: Accelerating Drug Discovery through Enhanced Literature Analysis
08:30 – 09:30, 25 June 2025
This talk explores the transformative impact of Artificial Intelligence (AI) on the research lifecycle, with a focus on its application in accelerating drug discovery. It introduces the concept of the “Perpetual Research Cycle,” where AI facilitates the continuous flow from data to papers and knowledge, driving innovation in scientific research. The discussion will highlight how AI tools enhance critical stages of this cycle, particularly in literature analysis and review, which are fundamental to drug discovery.
The presentation will showcase specific AI-driven solutions that streamline systematic literature reviews, enable continuous monitoring of relevant publications, and enhance the precision and efficiency of data extraction from scientific literature. By automating and accelerating these processes, AI empowers researchers to derive deeper insights from vast amounts of scientific data, ultimately leading to faster and more effective drug discovery. The talk will also address key considerations for responsible AI implementation in research, ensuring trust, accuracy, and reliability in the quest for new therapies.
Roundtable discussion: AI in Literature Reviews: Practical Strategies and Future Directions
11:20 – 12:20, 25 June 2025
Data Quality track
Join this interactive roundtable discussion to dive deeper into the role of AI in Systematic Literature Reviews for drug discovery. We’ll explore real-world applications, challenges, and best practices for integrating AI-driven tools into literature review workflows. Share experiences, discuss implementation strategies, and uncover new ways to leverage AI for faster, more precise evidence synthesis. Whether you’re exploring AI adoption or optimizing existing processes, this roundtable offers a collaborative space to exchange ideas and drive innovation in drug discovery research.
- Explore real-world applications, challenges, and best practices for AI-driven literature reviews in drug discovery
- Discuss implementation strategies and share experiences with AI integration in review workflows
- Uncover new ways to leverage AI for faster, more precise evidence synthesis
- Engage in a collaborative discussion on optimizing AI adoption and improving existing processes
- Exchange ideas and insights to drive innovation in drug discovery research
Dr Mark Hahnel
VP Open Research
Dr Mark Hahnel
VP Open Research
Mark Hahnel is the VP Open Research at Digital Science. He is the founder of Figshare, which he created whilst completing his PhD in stem cell biology at Imperial College London. He is passionate about open science and the potential it has to revolutionize the research community. Mark sits on the board of DataCite and the advisory board for Directory of Open Access Journals (DOAJ) and re3data.